Exciting news about the potential of GLP-1 RAs in reducing obesity-related cancer risks! As someone with multiple family members affected by cancer, this area of research is deeply personal. However, it's important to approach these findings with a "dose" of caution. While the study offers signals that are positive, we must recognize the limitations and avoid prematurely signaling these results as definitive to prevent a further rush on the drugs when there is already a shortage. The reliance on data from the TriNetX database, the exclusion of certain patient populations, and the inherent limitations of propensity score matching all point to areas where further review is needed. Also, the paradoxical finding that GLP-1 RAs offer superior mortality benefits despite less weight loss compared to bariatric surgery raises an area for further discussion. It's essential that to balance enthusiasm with a criticism and not fall into an area of confirmation bias one way or the other! https://buff.ly/45vQJWE #GLP1RA #Healthcare #EvidenceBasedMedicine #AOMs #WeightLoss
Steven Kuyan’s Post
More Relevant Posts
-
Experienced professional leader with a strong background in 501(c)(3) and 501(c)(6) non-profit medical associations and healthcare organizations.
🔬 Colorectal Cancer Prevention Alert! Referring large nonpedunculated colorectal polyps (LNPCPs) to specialized centers ensures better outcomes! 📈 In ASGE’s GIE September issue, review the study that highlights advanced resection techniques like ESD & EMR are setting new standards in care. Photodocumentation is now crucial for accurate referrals! 📸 Key takeaway: Referring LNPCP cases to a tertiary center boosts success! Learn more about the suggested referral standards for LNPCP resection and the importance of photodocumentation. 📸. 📄 https://lnkd.in/gndBSwFg #ColorectalCancer #GIEndoscopy #ASGE
Establishment of standards for the referral of large nonpedunculated colorectal polyps: an international expert consensus using a modified Delphi process
giejournal.org
-
📃Scientific paper: Validation of the DIGEST-FEES as a Global Outcome Measure for Pharyngeal Dysphagia in Parkinson’s Disease Abstract: Flexible Endoscopic Evaluation of Swallowing (FEES) is one of two diagnostic gold standards for pharyngeal dysphagia in Parkinson's disease (PD), however, validated global outcome measures at the patient level are widely lacking. The Dynamic Imaging Grade of Swallowing Toxicity for Flexible Endoscopic Evaluation of Swallowing (DIGEST-FEES) represents such an outcome measure but has been validated primarily for head and neck cancer collectives. The objective of this study was, therefore, to investigate the validity of the DIGEST-FEES in patients with PD. Content validity was evaluated with a modified Delphi expert survey. Subsequently, 66 FEES videos in PD patients were scored with the DIGEST-FEES. Criterion validity was determined using Spearman's correlation coefficient between the DIGEST-FEES and the Penetration-Aspiration Scale (PAS), the Yale-Residue-Rating-Scale, the Functional-Oral-Intake-Scale (FOIS), and the swallowing-related Unified-Parkinson-Disease-Rating-Scale (UPDRS) items. Inter-rater reliability was determined using 10 randomly selected FEES-videos examined by a second rater. As a result, the overall DIGEST-FEES-rating exhibited significant correlations with the Yale-Valleculae-Residue-Scale ( r = 0.84; p < 0.001), the Yale-Pyriform-Sinus-Residue-Scale ( r = 0.70; p < 0.001), the FOIS ( r = − 0.55, p < 0.001), and the UPDRS-Swallowing-Item-Score ( r = 0.42, p < 0.001). Further, the DIGEST-FEES-safety subscore correlated with the PAS ( r = 0... Continued on ES/IODE ➡️ https://etcse.fr/tsrBe ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.
Validation of the DIGEST-FEES as a Global Outcome Measure for Pharyngeal Dysphagia in Parkinson’s Disease
ethicseido.com
-
Glioblastoma (GBM) is a highly aggressive brain tumor with a median survival rate of 12 to 15 months under standard care, which includes surgery, radiation, and chemotherapy. The most common form of brain cancer in adults, GBM is challenging to treat due to its complex genetic makeup and the difficult environment it creates within the body. Despite aggressive treatment, fewer than 5% of patients survive beyond three years. A recent case report documented the three-year experience of a 64-year-old female patient diagnosed with GBM who undertook intensive ketogenic metabolic therapy (KMT) as an adjunct to standard treatment protocols. KMT involved prolonged fasting, time-restricted eating, and a modified ketogenic diet to lower the glucose ketone index (GKI) and target cancer cells' metabolic weaknesses. After commencing KMT, the patient maintained an average GKI of 1.65 in the first year and 2.02 in the second year. She achieved tumor stability, with no progression on imaging. She also experienced a decrease in chronic pain, an improved sense of well-being, and a healthy reduction in BMI from 28 to 20.5. In the third year, after the death of a family member, dramatically increased stress, and slightly reduced adherence to KMT resulting in a higher average GKI of 3.2, signs of cancer progression reappeared. Further treatments were initiated, but the patient's condition declined. She passed away in the 38th month after diagnosis. This case suggests that integrating KMT with standard GBM treatments may help maintain tumor stability and improve quality of life. Adherence to KMT was linked to positive outcomes, while relaxation of the diet coincided with disease progression, suggesting that a consistently low GKI may be key to KMT's effectiveness. Further research is needed to confirm these findings. — Phillips MCL, Thotathil Z, Dass PH, Ziad F, Moon BG. Ketogenic metabolic therapy in conjunction with standard treatment for glioblastoma: a case report. Oncol Let. 2024 Mar 26;27(5):230. doi: 10.3892/ol.2024.14363. 📌 Link to study: https://lnkd.in/gB9g9Q7x 📌 Find more research summaries on our website: https://lnkd.in/gKeXEcEN #Keto #Ketogenicdiet #Glioblastoma #Research
-
-
📃Scientific paper: Validation of the DIGEST-FEES as a Global Outcome Measure for Pharyngeal Dysphagia in Parkinson’s Disease Abstract: Flexible Endoscopic Evaluation of Swallowing (FEES) is one of two diagnostic gold standards for pharyngeal dysphagia in Parkinson's disease (PD), however, validated global outcome measures at the patient level are widely lacking. The Dynamic Imaging Grade of Swallowing Toxicity for Flexible Endoscopic Evaluation of Swallowing (DIGEST-FEES) represents such an outcome measure but has been validated primarily for head and neck cancer collectives. The objective of this study was, therefore, to investigate the validity of the DIGEST-FEES in patients with PD. Content validity was evaluated with a modified Delphi expert survey. Subsequently, 66 FEES videos in PD patients were scored with the DIGEST-FEES. Criterion validity was determined using Spearman's correlation coefficient between the DIGEST-FEES and the Penetration-Aspiration Scale (PAS), the Yale-Residue-Rating-Scale, the Functional-Oral-Intake-Scale (FOIS), and the swallowing-related Unified-Parkinson-Disease-Rating-Scale (UPDRS) items. Inter-rater reliability was determined using 10 randomly selected FEES-videos examined by a second rater. As a result, the overall DIGEST-FEES-rating exhibited significant correlations with the Yale-Valleculae-Residue-Scale ( r = 0.84; p < 0.001), the Yale-Pyriform-Sinus-Residue-Scale ( r = 0.70; p < 0.001), the FOIS ( r = − 0.55, p < 0.001), and the UPDRS-Swallowing-Item-Score ( r = 0.42, p < 0.001). Further, the DIGEST-FEES-safety subscore correlated with the PAS ( r = 0... Continued on ES/IODE ➡️ https://etcse.fr/tsrBe ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.
Validation of the DIGEST-FEES as a Global Outcome Measure for Pharyngeal Dysphagia in Parkinson’s Disease
ethicseido.com
-
Gillies McIndoe: Treating meningioma Dr Matthew Munro from Gillies McIndoe Research Institute has been awarded a Neurological Foundation of NZ Small Project Grant to explore the effectiveness of repurposed drugs in treating meningioma, the most common brain tumour in New Zealand. With around 300 new cases annually, meningioma symptoms vary based on tumour location and can include vision or hearing loss, dizziness, headaches, seizures, and depression. Surgery is the primary treatment, often supplemented by radiation, but high-grade cases frequently recur due to incomplete removal and cancer spread. Currently, no chemotherapy drugs exist for meningioma. Matt’s research involves treating meningioma cells with pre-selected drugs to study their effects on cell behaviour and metabolism. Repurposing existing drugs offers a cost-effective, accessible option, potentially reducing the need for surgery and easing the burden on patients. #MeningiomaResearch #BrainTumourAwareness #GilliesMcIndoe #NeurologicalHealth #CancerResearch #RepurposedDrugs #InnovativeMedicine #MedicalResearch #HealthInnovation #patientcare #iranzresearch https://lnkd.in/gG-veJyw
Meningioma Cancer Research — Gillies McIndoe Research Institute
gmri.org.nz
-
Chief Biohacker TrueMedX & Neighborly Wellness | Regulatory Consultant & Expert Speaker | Contributor, American Journal of Endocannabinoid Medicine | Host of 'Chip Talks' Podcast | Chickasaw Citizen
Keto, with the proper ratio of o3/o6 is a great way to fight cancer. However, at baseline you need to know this: You body has two ways to kill cancer. A process called autophaghy and a protein called P53. When you are in a FED state (eating and five hours post eating) you turn both of these process OFF. When you are in a FASTED state (five hours past your last meal) you turn them ON. Eating breakfast, lunch, and dinner, as suggested by our USDA, will NOT allow a cancer patient to get much help from their own bodies at fighting the cancer. Intermittent fasting WILL ALLOW the body to assist in the fight against cancer. Eating in a window (start eating at noon and stop by 6,7,8p) and NOT eating outside that window is a great strategy for cancer patients to put their bodies into a healing state.
Glioblastoma (GBM) is a highly aggressive brain tumor with a median survival rate of 12 to 15 months under standard care, which includes surgery, radiation, and chemotherapy. The most common form of brain cancer in adults, GBM is challenging to treat due to its complex genetic makeup and the difficult environment it creates within the body. Despite aggressive treatment, fewer than 5% of patients survive beyond three years. A recent case report documented the three-year experience of a 64-year-old female patient diagnosed with GBM who undertook intensive ketogenic metabolic therapy (KMT) as an adjunct to standard treatment protocols. KMT involved prolonged fasting, time-restricted eating, and a modified ketogenic diet to lower the glucose ketone index (GKI) and target cancer cells' metabolic weaknesses. After commencing KMT, the patient maintained an average GKI of 1.65 in the first year and 2.02 in the second year. She achieved tumor stability, with no progression on imaging. She also experienced a decrease in chronic pain, an improved sense of well-being, and a healthy reduction in BMI from 28 to 20.5. In the third year, after the death of a family member, dramatically increased stress, and slightly reduced adherence to KMT resulting in a higher average GKI of 3.2, signs of cancer progression reappeared. Further treatments were initiated, but the patient's condition declined. She passed away in the 38th month after diagnosis. This case suggests that integrating KMT with standard GBM treatments may help maintain tumor stability and improve quality of life. Adherence to KMT was linked to positive outcomes, while relaxation of the diet coincided with disease progression, suggesting that a consistently low GKI may be key to KMT's effectiveness. Further research is needed to confirm these findings. — Phillips MCL, Thotathil Z, Dass PH, Ziad F, Moon BG. Ketogenic metabolic therapy in conjunction with standard treatment for glioblastoma: a case report. Oncol Let. 2024 Mar 26;27(5):230. doi: 10.3892/ol.2024.14363. 📌 Link to study: https://lnkd.in/gB9g9Q7x 📌 Find more research summaries on our website: https://lnkd.in/gKeXEcEN #Keto #Ketogenicdiet #Glioblastoma #Research
-
-
📃Scientific paper: Validation of the DIGEST-FEES as a Global Outcome Measure for Pharyngeal Dysphagia in Parkinson’s Disease Abstract: Flexible Endoscopic Evaluation of Swallowing (FEES) is one of two diagnostic gold standards for pharyngeal dysphagia in Parkinson's disease (PD), however, validated global outcome measures at the patient level are widely lacking. The Dynamic Imaging Grade of Swallowing Toxicity for Flexible Endoscopic Evaluation of Swallowing (DIGEST-FEES) represents such an outcome measure but has been validated primarily for head and neck cancer collectives. The objective of this study was, therefore, to investigate the validity of the DIGEST-FEES in patients with PD. Content validity was evaluated with a modified Delphi expert survey. Subsequently, 66 FEES videos in PD patients were scored with the DIGEST-FEES. Criterion validity was determined using Spearman's correlation coefficient between the DIGEST-FEES and the Penetration-Aspiration Scale (PAS), the Yale-Residue-Rating-Scale, the Functional-Oral-Intake-Scale (FOIS), and the swallowing-related Unified-Parkinson-Disease-Rating-Scale (UPDRS) items. Inter-rater reliability was determined using 10 randomly selected FEES-videos examined by a second rater. As a result, the overall DIGEST-FEES-rating exhibited significant correlations with the Yale-Valleculae-Residue-Scale ( r = 0.84; p < 0.001), the Yale-Pyriform-Sinus-Residue-Scale ( r = 0.70; p < 0.001), the FOIS ( r = − 0.55, p < 0.001), and the UPDRS-Swallowing-Item-Score ( r = 0.42, p < 0.001). Further, the DIGEST-FEES-safety subscore correlated with the PAS ( r = 0... Continued on ES/IODE ➡️ https://etcse.fr/tsrBe ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.
Validation of the DIGEST-FEES as a Global Outcome Measure for Pharyngeal Dysphagia in Parkinson’s Disease
ethicseido.com
-
📃Scientific paper: Validation of the DIGEST-FEES as a Global Outcome Measure for Pharyngeal Dysphagia in Parkinson’s Disease Abstract: Flexible Endoscopic Evaluation of Swallowing (FEES) is one of two diagnostic gold standards for pharyngeal dysphagia in Parkinson's disease (PD), however, validated global outcome measures at the patient level are widely lacking. The Dynamic Imaging Grade of Swallowing Toxicity for Flexible Endoscopic Evaluation of Swallowing (DIGEST-FEES) represents such an outcome measure but has been validated primarily for head and neck cancer collectives. The objective of this study was, therefore, to investigate the validity of the DIGEST-FEES in patients with PD. Content validity was evaluated with a modified Delphi expert survey. Subsequently, 66 FEES videos in PD patients were scored with the DIGEST-FEES. Criterion validity was determined using Spearman's correlation coefficient between the DIGEST-FEES and the Penetration-Aspiration Scale (PAS), the Yale-Residue-Rating-Scale, the Functional-Oral-Intake-Scale (FOIS), and the swallowing-related Unified-Parkinson-Disease-Rating-Scale (UPDRS) items. Inter-rater reliability was determined using 10 randomly selected FEES-videos examined by a second rater. As a result, the overall DIGEST-FEES-rating exhibited significant correlations with the Yale-Valleculae-Residue-Scale ( r = 0.84; p < 0.001), the Yale-Pyriform-Sinus-Residue-Scale ( r = 0.70; p < 0.001), the FOIS ( r = − 0.55, p < 0.001), and the UPDRS-Swallowing-Item-Score ( r = 0.42, p < 0.001). Further, the DIGEST-FEES-safety subscore correlated with the PAS ( r = 0... Continued on ES/IODE ➡️ https://etcse.fr/tsrBe ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.
Validation of the DIGEST-FEES as a Global Outcome Measure for Pharyngeal Dysphagia in Parkinson’s Disease
ethicseido.com
-
📃Scientific paper: Validation of the DIGEST-FEES as a Global Outcome Measure for Pharyngeal Dysphagia in Parkinson’s Disease Abstract: Flexible Endoscopic Evaluation of Swallowing (FEES) is one of two diagnostic gold standards for pharyngeal dysphagia in Parkinson's disease (PD), however, validated global outcome measures at the patient level are widely lacking. The Dynamic Imaging Grade of Swallowing Toxicity for Flexible Endoscopic Evaluation of Swallowing (DIGEST-FEES) represents such an outcome measure but has been validated primarily for head and neck cancer collectives. The objective of this study was, therefore, to investigate the validity of the DIGEST-FEES in patients with PD. Content validity was evaluated with a modified Delphi expert survey. Subsequently, 66 FEES videos in PD patients were scored with the DIGEST-FEES. Criterion validity was determined using Spearman's correlation coefficient between the DIGEST-FEES and the Penetration-Aspiration Scale (PAS), the Yale-Residue-Rating-Scale, the Functional-Oral-Intake-Scale (FOIS), and the swallowing-related Unified-Parkinson-Disease-Rating-Scale (UPDRS) items. Inter-rater reliability was determined using 10 randomly selected FEES-videos examined by a second rater. As a result, the overall DIGEST-FEES-rating exhibited significant correlations with the Yale-Valleculae-Residue-Scale ( r = 0.84; p < 0.001), the Yale-Pyriform-Sinus-Residue-Scale ( r = 0.70; p < 0.001), the FOIS ( r = − 0.55, p < 0.001), and the UPDRS-Swallowing-Item-Score ( r = 0.42, p < 0.001). Further, the DIGEST-FEES-safety subscore correlated with the PAS ( r = 0... Continued on ES/IODE ➡️ https://etcse.fr/tsrBe ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.
Validation of the DIGEST-FEES as a Global Outcome Measure for Pharyngeal Dysphagia in Parkinson’s Disease
ethicseido.com
-
🎯 Comprehensive Review: Malignant Transformation and Long-Term Outcomes of Oral and Laryngeal Leukoplakia 🎯 This detailed study examines the higher risk of malignant transformation in laryngeal leukoplakia compared to oral leukoplakia: ✅ 50% vs. 21.7% malignant transformation risk for laryngeal vs. oral leukoplakia ✅ Dysplasia is a key predictor for both types ✅ Oral leukoplakia without dysplasia shows a lower transformation risk (3.9%) 🧠 Key Insight: High-risk patients need complete excision and long-term follow-up for early cancer detection and management of late-stage malignant events. Botond Bukovszky Dr., János Fodor, Erika Tóth, Zsuzsa Kocsis, Ferenc Oberna, Örs Ferenczi M.D., Csaba Polgár 📑 CME Credit: 1.0 AMA PRA Category 1 Credit https://lnkd.in/drB8SgJM #Leukoplakia #HeadAndNeckCancer #Otolaryngology #Oncology #CME #CancerResearch #LongTermCare
Acapedia CME | Oral vs Laryngeal Leukoplakia Malignancy Risks
acapedia.com
Healthtech Exec Committed to Patient-First Innovation | Ro Employee #3 | Startup Leader | Strategic Advisor | Builder of High-Performing Teams
2moWe need many more details to understand this study itself notwithstanding your caveats about propensity score matching. How long did people have obesity? What were their family histories? What other risk factors did they have? And many other questions... Much more research will have to be done to disentangle these questions, but we cannot exclude weight-independent effects of both bariatric surgery and GLP-1s as possible protective factors. For example, we know bariatric surgery changes hormone levels (ghrelin is most notable in LSG while GLP-1 is most notable in RYGB), the microbiome, and bile acid levels just to name a few. On the other hand, GLP-1s affect many organs, including the brain, heart, kidneys, etc. and also have positive impacts on systemic inflammation (they lower CRP). I still agree the findings of greater protection from GLP-1s than surgery are surprising and something that shlould give us pause before overinterpreting.